Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Hrk supply Ozenoxacin Raw materials powder
Product Overview:
Ozefloxacin is a non-fluoroquinolone antibiotic that resists most microorganisms isolated from skin and soft tissue infections and is indicated for the topical treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes infection in adults and children 2 months of age and older. Liwei Pharmaceutical intends to introduce oxefloxacin apis and hopes to cooperate with domestic manufacturers.
Hrk supply Ozenoxacin Raw materials powder Attributes
CAS:245765-41-7
MF:C21H21N3O3
MW:363.41
EINECS:105-745-2
Specification: 99% min Ozenoxacin powder
Sample:Ozenoxacin powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Store at -20°C
Shelf Life: 2 Years
Test Method: HPLC
Hrk supply Ozenoxacin Raw materials powder Details
Ozenoxacin powder of Usage and Synthesis.
Ozefloxacin is a quinolone antibacterial drug developed by Ferrer Internacional Ltd. of Spain, purchased by Medimetriks Pharmaceuticals of the United States and granted exclusive commercialization rights in the United States, and was approved by the Ministry of Health, Labor and Welfare of Japan in September 2015, becoming the world's first approved new molecular entity. It was approved by the US FDA on December 11, 2017. Ozefloxacin acts by inhibiting bacterial DNA replicase, DNA cyclase A and topoisomerase IV. Ozefloxacin is the third non-fluoroquinolone antibiotic approved in the world after Nenofloxacin and Garefloxacin. In clinical trials, Ozefloxacin was used to treat skin and soft tissue infections, and the efficacy was superior to mupirocin, with no significant adverse effects. The inhibitory effect of ozefloxacin on MRSA, methicillin-sensitive Staphylococcus aureus (MSSA) and ofloxacin-resistant Staphylococcus aureus was significantly stronger than that of nafloxacin, ofloxacin, levofloxacin, chlorlincomycin, erythromycin and gentamicin. Ozefloxacin has strong bactericidal activity and can be used as a new quinolone with a short course of treatment and a good clinical application prospect.
Uses of Ozenoxacin.
Ozefloxacin is primarily used to treat skin and soft tissue infections.
Ozenoxacin (Ozenoxacin) is an antimicrobial agent that primarily targets microorganisms isolated from skin and soft tissue infections. It is an antibacterial agent capable of resisting many kinds of microorganisms and is particularly suitable for treating infections caused by these microorganisms. ozefloxacin is mainly used in skin topical preparations, In vitro release studies have shown that ozefloxacin is effective against microorganisms that cause skin and soft tissue infections, , thereby helping patients recover.
In vitro release of ozefloxacin was studied using a Franz diffusion cell method, using an artificial membrane and a specific receiving solution, the release of the drug in the artificial membrane was determined by high performance liquid chromatography, and to evaluate the consistency of release in vitro. The results showed that ozefloxacin and the reference preparation had consistent release behavior in vitro, indicating that the application of ozefloxacin in skin topical preparations has good stability and effectiveness.
Pharmacological action of Ozenoxacin.
Product Methods of Bulk Ozenoxacin powder.
